Small molecule · Cytotoxic, directed at guanine (DNA) · developed by Merck Sharp Dohme
Temodar (temozolomide) is an oral alkylating agent that converts nonenzymatically at physiologic pH to MTIC, which methylates DNA mainly at the O6 and N7 positions of guanine, causing DNA double-strand breaks and cell death. It is used in the treatment of glioblastoma and anaplastic astrocytoma, and is studied in other glioma and brain tumor types.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Feb 20, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06161974 | Phase 2 | High Grade Glioma | Recruiting | RIGL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AstrocytomaAstrocytoma, Grade IIIAstrocytoma, Grade IVDiffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-MutantHigh Grade GliomaIDH1 MutationIDH1 R132IDH1 R132CIDH1 R132HMetastatic Brain TumorSpinal TumorThalamus TumorWHO Grade III Glioma
Updated Nov 1, 2026.